Medroxiprogesterona [Inn-Spanish] en es it fr

Medroxiprogesterona [Inn-Spanish] Brand names, Medroxiprogesterona [Inn-Spanish] Analogs

Medroxiprogesterona [Inn-Spanish] Brand Names Mixture

  • Lunelle (Medroxyprogesterone + Estradiol)

Medroxiprogesterona [Inn-Spanish] Chemical_Formula


Medroxiprogesterona [Inn-Spanish] RX_link

Medroxiprogesterona [Inn-Spanish] fda sheet

Medroxiprogesterona_[Inn-Spanish] FDA

Medroxiprogesterona [Inn-Spanish] msds (material safety sheet)

Medroxiprogesterona [Inn-Spanish] Synthesis Reference

P. Ruggieri, C. Ferrari, U.S. Pat. 3,043,832 (1962)

Medroxiprogesterona [Inn-Spanish] Molecular Weight

344.488 g/mol

Medroxiprogesterona [Inn-Spanish] Melting Point

220 - 223.5 oC

Medroxiprogesterona [Inn-Spanish] H2O Solubility


Medroxiprogesterona [Inn-Spanish] State


Medroxiprogesterona [Inn-Spanish] LogP


Medroxiprogesterona [Inn-Spanish] Dosage Forms

Tablets; Depo injection

Medroxiprogesterona [Inn-Spanish] Indication

Used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions.

Medroxiprogesterona [Inn-Spanish] Pharmacology

Medroxyprogesterone is a synthetic progestin more potent than progesterone.

Medroxiprogesterona [Inn-Spanish] Absorption

Rapidly absorbed from GI tract

Medroxiprogesterona [Inn-Spanish] side effects and Toxicity

Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.

Medroxiprogesterona [Inn-Spanish] Patient Information

Medroxiprogesterona [Inn-Spanish] Organisms Affected

Humans and other mammals